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Recently, the first genome-wide association study (GWAS) of alopecia areata (AA) was conducted in a North-
American sample, and this identified eight susceptibility loci surpassing genome-wide significance. The aim
of the present follow-up association analysis was to confirm five of these eight loci (single-nucleotide
polymorphisms (SNPs) from the CTLA4, IL-2RA, and HLA regions were not included due to previous own
findings) and test 12 other loci from the GWAS, which did not surpass the threshold for genome-wide
significance. Twenty-three SNPs from the 17 loci were investigated using a sample of 1,702 Central European AA
patients and 1,723 controls. Of the five loci with previously reported genome-wide significance, association was
confirmed for all of these: ULBP3/ULBP6, PRDX5, IL-2/IL-21, STX17, and IKZF4/ERBB3 (P-value o0.05). To detect
robust evidence for association among the 12 other loci, a meta-analysis of the present association data and the
data of the recent GWAS was performed. Genome-wide significant association was found for rs20541
(Pcomb¼ 7.52 1010; odds ratio (OR)¼ 1.30 (1.23–1.38)) and rs998592 (Pcomb¼ 1.11 1011; OR¼ 1.28 (1.21–1.36)),
thus establishing IL-13 and KIAA0350/CLEC16A as susceptibility loci for AA. Interestingly, IL-13 and KIAA0350/
CLEC16A are susceptibility loci for other autoimmune diseases, supporting the hypothesis of shared pathways
of autoimmune susceptibility.
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INTRODUCTION
Alopecia areata (AA; MIM 104,000) is a common hair loss
disorder that affects B1–2% of the general population,
including both sexes and all age groups (Safavi et al.,
1995). Research has established that AA may be familial,
and recurrence risks of 5–8% have been reported in first-
degree relatives of affected individuals (Jackow et al., 1998;
Blaumeiser et al., 2006). The pattern of familiality suggests
that the genetic basis is multifactorial. Although the scalp is
the most commonly affected site in AA, all hair-bearing areas
of the skin, including the eyebrows and eyelashes, may
be affected. Episodes of hair loss typically commence with
the development of isolated hairless patches, which then
progress centrifugally and may coalesce. AA is divided into
three main clinical subtypes on the basis of the degree of hair
loss and the affected sites: patchy AA, affecting localized
areas of the scalp and/or body hair; AA totalis (AT), affecting
the entire scalp; and AA universalis (AU), affecting the entire
scalp and body (Olsen et al., 2004). The clinical course may
be characterized by complete remission, chronicity, or
progression toward AT or AU. The hair loss itself—especially
its unpredictable course—causes substantial psychological
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distress in the majority of those affected. The etiopathogen-
esis of AA is not entirely understood. However, immuno-
logical and association studies are generating accumulating
support for the hypothesis that innate and acquired immunity
are implicated (Gilhar et al., 2007; Petukhova et al., 2010).
The first genome-wide association study (GWAS) of AA
was recently published, in the following designated as US
GWAS (Petukhova et al., 2010). This involved a total of 1,054
AA cases (US patients of self-reported European ancestry) and
3,278 controls from various samples, all of which were
genotyped with Illumina BeadChips (610K and 550K).
Genome-wide significance (Pp5 107) was obtained for
139 single-nucleotide polymorphisms (SNPs) in eight differ-
ent genomic regions. Most of these regions are implicated in
autoimmunity and have a crucial role in T-cell-mediated
pathways. These susceptibility loci include the following
genes: cytotoxic T lymphocyte–associated antigen 4 (CTLA4)
on chromosome 2q33.2; IL-2/IL-21 on chromosome 4q27;
IL-2 receptor A (IL-2RA; CD25) on chromosome 10p15.1;
peroxiredoxin 5 (PRDX5) on chromosome 11q13; syntaxin
17 (STX17) on chromosome 9q31.1; the genes Eos (also
known as Ikaros family zinc-finger 4; IKZF4) and the erythro-
blastic leukemia viral oncogene homolog 3 (ERBB3) on
chromosome 12q13; cytomegalovirus UL16–binding protein
(ULBP) on chromosome 6q25.1, comprising the ULBP3 and
ULPB6 genes; and several genes in the HLA region on
chromosome 6p21.3.
The aims of the present study were to provide independent
replication of the genome-wide significant loci identified in
the recent US GWAS, and to examine the contribution of 12
other loci from the US GWAS, which did not surpass the
threshold for genome-wide significance, which is generally
set to Pp5108. A total of 23 SNPs from the US GWAS
were selected and genotyped using a sample of 1,702 Central
European AA patients and 1,723 controls (see Materials and
Methods).
RESULTS
From the five genomic regions with Pp5 107 in the
US GWAS, replication was achieved for markers at all of
these loci (Table 1). The strongest association was found
for the two variants in the ULBP gene cluster (rs9479482:
P¼1.22 1013; odds ratio (OR): 1.50 (1.35–1.66); and
rs2009345: P¼ 1.411011; OR: 1.45 (1.30–1.61)), fol-
lowed by the variant in the PRDX5 locus (rs694739:
P¼4.03 105; OR: 1.26 (1.13–1.40)), two variants in the
IL21 locus (rs2137497: P¼0.001; OR: 1.19 (1.07–1.32);
rs7682241: P¼0.02; OR: 1.14 (1.02–1.27)), the variant in the
STX17 locus (rs10760706: P¼ 0.009; OR: 1.16 (1.04–1.29)),
and one variant in the IKZF4/ERBB3 locus (rs1701704:
P¼0.016; OR: 1.14 (1.02–1.27)). The ORs in the present
study were all smaller than those reported in the US GWAS.
This is likely to have been due to the ‘‘winner’s curse’’
effect. This is well recognized in GWAS, and renders
the estimation of effect sizes from GWAS data unreliable
(Garner, 2007). However, for each variant, the direction
of the association was the same as that observed in the
US GWAS.
Of the 15 variants that did not surpass the threshold of
genome-wide significance in the US GWAS, only rs20541
(IL13) and rs998592 (KIAA0350/CLEC16A) showed a nomin-
ally significant association in the present sample (P¼0.0002;
OR: 1.26 (1.12–1.43) and P¼ 2.45107; OR: 1.32
(1.19–1.47), respectively).
To obtain robust evidence for association, we performed a
meta-analysis of the present association data and the data of
the US GWAS (Table 2). In this meta-analysis, the variants
rs20541 and rs998592 reached genome-wide significance.
The P-value for rs998592 was 1.11 1011 (OR: 1.28 (1.21–
1.36)). The marker rs20541 achieved a P-value of 7.52
1010 (OR: 1.30 (1.23–1.38)). Therefore, IL13 and the C-type
lectin domain family 16, member A (KIAA0350/CLEC16A)
were identified as two AA susceptibility loci that showed
genome-wide significant association. To further analyze the
involvement of these two genes in pathophysiology of hair,
we analyzed the mRNA expression in skin and complete hair
follicles extracted from different healthy controls. After
extraction of total RNA with the RNeasy Plus Micro Kit
(Qiagen, Hilden, Germany), we performed a semiquantitative
two-step real-time PCR using random hexamers in the first
reaction and gene-specific primers in the second reaction
(IL13-F: 50-TGGGGAAGACTGTGGCTGC-30; IL13-R: 50-ACT
CGTTGGCTGAGAGCTGG-30; CLEC16A-F: 50-TTTGCATCG
GTGGACAAGG-30; CLEC16A-R: 50-ACTGGTCAGGAAGGT
GAGGC-30). Interestingly, IL13 and KIAA0350/CLEC16A
expression was observed in hair follicles and skin, which
points to an involvement of these genes in terms of hair
biology (Figure 1).
Additional analyses were then performed. An interaction
analysis for all associated loci was negative. To exclude the
possibility that the association findings for IL13 were the
result of comorbidity with atopic dermatitis (AD), a separate
analysis was performed for AA patients with AD and AA
patients without AD. In both groups, significant association
was found for rs20541. Furthermore, no significant differ-
ences in the ORs were observed between the two groups.
Thus, an effect of comorbidity with AD is highly unlikely
(results not shown).
DISCUSSION
IL13 is a member of the cytokine group, and is synthesized by
activated T helper 2 cells. It is an essential effector in the
recruitment of inflammatory cells, and is thought to activate
IgE, as well as the production and secretion of mucin (Lloyd
and Hessel, 2010). The variant rs20541, which achieved
genome-wide significance in the present meta-analysis, and
variants in linkage disequilibrium with rs20541 have been
reported to be associated with autoimmune diseases such as
psoriasis, arthritis, and asthma. As all of the observed associ-
ations are in the same direction, an overlap in the etiology of
these diseases is likely (Beghe et al., 2010; Bottema et al.,
2010; Lloyd and Hessel, 2010; Bowes et al., 2011). Interes-
tingly, atopic diseases such as allergic asthma are frequent
comorbid disorders in patients with AA (Chu et al., 2011).
KIAA0350/CLEC16A is located on chromosome 16p13
and encodes a protein of as yet unknown function. It is
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supposed that KIAA0350/CLEC16A exerts its effects via
calcium-dependent or C-type lectin-binding structures.
KIAA0350/CLEC16A is mainly expressed in immune cells,
and is therefore assumed to be of crucial importance in
immune modulating processes (Martinez et al., 2010). Recent
studies have shown that genetic variants of the KIAA0350/
CLEC16A gene, including the variant rs998592 and variants
in linkage disequilibrium with rs998592, confer susceptibility
to the common autoimmune disorders such as multiple
sclerosis and type 1 diabetes (Zoledziewska et al., 2009;
Nischwitz et al., 2011; IMSGC, 2009). The variant rs998592
has been reported to be associated with multiple sclerosis,
and the direction of the association was the same as that
observed in the present AA sample (Nischwitz et al., 2011).
This provides further evidence that these two disorders and
AA have a shared etiology.
In conclusion, the present study replicated five AA
susceptibility loci—ULBP3 and ULBP6, PRDX5, IL-2/IL-21,
IKZF4/ERBB3, and STX17—identified in the US GWAS. Most
importantly, a meta-analysis of the present association data
and the data of the recent US GWAS provided genome-wide
significant support for the hypothesis that IL-13 and
KIAA0350/CLEC16A are important susceptibility loci for AA.
MATERIALS AND METHODS
For follow-up analysis of the US GWAS, we used a sample of 1,702
AA patients and 1,723 controls. An association analysis was
performed by comparing allele frequencies in patients and controls.
For the 12 loci that previously failed to surpass the threshold of
genome-wide significance, a meta-analysis of our present associa-
tion data and the US GWAS data was performed to achieve greater
power.
The study included 1,234 female and 468 male patients aged
5–88 years. Exclusion criteria for patients were the presence of
Down’s syndrome or Turner’s syndrome. The patients were recruited
from outpatient clinics in Belgium (Antwerp and Gent) and Germany
Table 1. Case–control association analysis in 1,702 alopecia areata patients and 1,723 controls
MAF2 P Allelic OR
SNP Position1 Gene symbol Allele (A/B) Ca Co Armitage (95% CI)3
rs2275909 6991259 CAMTA1 T/C 0.319 (C) 0.320 (C) 0.898 1.01 (0.90–1.12)
rs11590951 176589380 RASAL2 T/C 0.099 (T) 0.095 (T) 0.552 1.05 (0.89–1.25)
rs1531968 240025939 HDAC4 A/G 0.351 (G) 0.364 (G) 0.293 1.06 (0.95–1.18)
rs3912834 55017401 CACNA2D3 G/A 0.139 (G) 0.136 (G) 0.719 1.03 (0.89–1.19)
rs7684834 123260318 TRPC3 G/A 0.407 (G) 0.388 (G) 0.119 1.09 (0.98–1.21)
rs7683061 123407319 Tenr T/C 0.401 (T) 0.379 (T) 0.088 1.10 (0.99–1.22)
rs7682241 123743325 IL-21* A/C 0.367 (A) 0.338 (A) 0.02 1.14 (1.02–1.27)
rs2137497 123777704 IL-21* T/G 0.437 (T) 0.396 (T) 0.001 1.19 (1.07–1.32)
rs20541 132023863 IL-13 A/G 0.245 (A) 0.205 (A) 0.0002 1.26 (1.12–1.43)
rs9479482 150399705 ULBP6* T/C 0.360 (C) 0.457 (C) 1.221013 1.50 (1.35–1.66)
rs2009345 150431441 ULBP3* G/A 0.460 (G) 0.371 (G) 1.411011 1.45 (1.30–1.61)
rs7776857 22721293 IL-6 G/T 0.346 (G) 0.334 (G) 0.34 1.05 (0.95–1.18)
rs10488223 132436737 CHCHD3 T/C 0.049 (C) 0.053 (C) 0.413 1.10 (0.87–1.39)
rs10760706 101763513 STX17* C/T 0.332 (C) 0.300 (C) 0.009 1.16 (1.04–1.29)
rs694739 63853809 PRDX5* A/G 0.325 (G) 0.377 (G) 4.03105 1.26 (1.13–1.40)
rs1701704 54698754 IKZF4* G/T 0.348 (G) 0.318 (G) 0.016 1.14 (1.02–1.27)
rs705708 54775180 ERBB3* A/G 0.471 (A) 0.461 (A) 0.455 1.04 (0.94–1.15)
rs2069718 66836429 IFNG T/C 0.392 (T) 0.390 (T) 0.921 1.01 (0.90–1.12)
rs4913277 66868439 IL-26 T/C 0.371 (C) 0.377 (C) 0.622 1.03 (0.92–1.14)
rs998592 11107179 KIAA0350/CLEC16A C/T 0.378 (T) 0.446 (T) 2.45107 1.32 (1.19–1.47)
rs8060821 11241560 SOCS1 T/G 0.414 (G) 0.434 (G) 0.128 1.08 (0.98–1.20)
rs4798791 9245982 ANKRD12 G/A 0.382 (A) 0.382 (A) 0.955 1.00 (0.90–1.12)
rs1893217 12799340 PTPN2 C/T 0.176 (C) 0.159 (C) 0.082 1.13 (0.99–1.30)
Abbreviations: Ca, cases; CI, confidence interval; Co, controls; MAF, minor allele frequencies; OR, odds ratio; SNP, single-nucleotide polymorphism.
1In base pairs, NCBI build 36.
2MAF in parentheses.
3OR calculation based on the minor allele.
*These genes showed genome-wide significance in the US genome-wide association study.
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(Berlin, Bonn, Du¨sseldorf, Gießen, Hamburg, Mannheim, Munich,
and Mu¨nster), a private dermatology practice (Wesseling, Germany),
and via AA self-support groups. For all patients, the diagnosis of AA
was assigned by an experienced dermatologist. Clinical data were
obtained from all patients, including age at onset and family history.
Disease subtype was determined according to the AA investigation
assessment guidelines (Olsen et al., 2004), and patients were
categorized as having patchy AA, alopecia totalis (AT), alopecia
totalis/universalis (AT/AU), or alopecia universalis (AU). Patchy AA
is defined as one or more circumscribed patches of hair loss; AT is
defined as 100% loss of scalp hair without loss of body hair; AT/AU
is defined as 100% loss of scalp hair with variable loss of body hair;
and AU is defined as 100% loss of both scalp and body hair.
Assessment of severity was based on a lifetime perspective, and was
judged according to the most severe episode ever experienced.
Patients included in our study with AT, AT/AU, and AU were
classified as having severe AA (n¼ 880; 51,7%), whereas patients
with patchy AA (n¼ 822; 48,3%) were classified as having mild AA.
A family history of AA, defined as having at least one first- or second-
degree relative with AA, was reported by 494 of 1,702 patients
(29%). The controls were blood donors recruited at the University
of Bonn who were not specifically screened for the absence of AA.
All the study participants were of Central European origin. Ethics
approval was obtained from the respective ethics committees, and
all participants provided written informed consent before blood
sampling. The study was conducted in accordance with the
Declaration of Helsinki Principles. DNA was extracted from
peripheral blood leukocytes by salting out with saturated NaCl
solution according to standard methods, or by using a Chemagic
Magnetic Separation Module I (Chemagen, Baesweiler, Germany) in
accordance with the manufacturer’s instructions. Genomic DNA
was diluted in water to working concentrations of 10 ng ml1 for SNP
genotyping.
Table 2. Meta-analysis of data from the present association analysis and the US GWAS (fixed and random models)
Fixed model Random model
P P P P
SNP Position1 Gene symbol
Allele
(A/B)
European
sample US sample
Meta-
analysis2
Allelic OR
(95% CI)3 SE Random4
Allelic OR
(95% CI)3 SE Q5 I 2,6
rs2275909 6991259 CAMTA1 T/C 8.98 101 8.77 106 0.0014 1.13 (1.07–1.20) 0.039 0.344 1.13 (1.08–1.18) 0.027 0.0011 90.6
rs11590951 176589380 RASAL2 T/C 5.52 101 5.18 106 1.18 104 1.24 (1.16–1.37) 0.059 0.1823 1.24 (1.16–1.33) 0.044 0.0067 86.4
rs1531968 240025939 HDAC4 A/G 2.93 101 8.10 105 1.75 104 1.15 (1.08–1.22) 0.037 0.0739 1.15 (1.10–1.20) 0.026 0.0424 75.7
rs3912834 55017401 CACNA2D3 G/A 7.19 101 7.28 105 0.0108 1.15 (1.04–1.25) 0.054 0.4044 1.15 (1.07–1.22) 0.038 0.0022 89.3
rs7684834 123260318 TRPC3 G/A 1.19 101 8.43 107 1.65 106 1.19 (1.13–1.26) 0.037 0.0535 1.19 (1.14–1.24) 0.026 0.0156 82.9
rs7683061 123407319 Tenr T/C 8.84 102 5.42 107 9.71 107 1.20 (1.14–1.26) 0.037 0.0381 1.19 (1.14–1.25) 0.028 0.0211 81.2
rs20541 132023863 IL-13 A/G 2.23 104 1.87 106 7.5231010 1.30 (1.23–1.38) 0.043 7.52 1010 1.30 (1.25–1.36) 0.029 0.4935 0
rs7776857 22721293 IL-6 G/T 3.40 101 7.72 105 3.27 104 1.15 (1.09–1.21) 0.038 0.0961 1.14 (1.10–1.19) 0.024 0.0339 77.8
rs10488223 132436737 CHCHD3 T/C 4.13 101 3.07 105 5.67 104 1.36 (1.19–1.54) 0.089 0.1673 1.40 (1.27–1.52) 0.065 0.0072 86.2
rs2069718 66836429 IFNG T/C 9.21 101 1.55 105 0.0034 1.12 (1.04–1.19) 0.039 0.34 1.12 (1.07–1.17) 0.024 0.0018 89.8
rs4913277 66868439 IL-26 T/C 6.22 101 9.85 105 0.0015 1.13 (1.05–1.20) 0.038 0.196 1.13 (1.07–1.18) 0.028 0.015 83.1
rs998592 11107179 KIAA0350/CLEC16A C/T 2.45 107 1.77 105 1.1131011 1.28 (1.21–1.36) 0.037 1.11 1011 1.28 (1.23–1.34) 0.026 0.4546 0
rs8060821 11241560 SOCS1 T/G 1.28 101 1.16 105 1.68 105 1.17 (1.10–1.25) 0.037 0.0405 1.17 (1.12–1.22) 0.027 0.037 77
rs4798791 9245982 ANKRD12 G/A 9.55 101 3.59 105 0.0031 1.12 (1.04–1.19) 0.038 0.3042 1.12 (1.07–1.17) 0.025 0.0039 88
rs1893217 12799340 PTPN2 C/T 8.19 102 4.09 106 3.03 106 1.25 (1.17–1.34) 0.048 0.0175 1.24 (1.17–1.31) 0.035 0.0566 72.5
Abbreviations: CI, confidence interval; GWAS, genome-wide association study; OR, odds ratio; SNP, single-nucleotide polymorphism.
1In base pairs, NCBI build 36.
2Combined P-values from the Central-European and US samples (meta-analysis), meta-analysis with fixed-effects models.
3OR calculation based on the minor allele.
4P-values combined from the Central-European and US samples (meta-analysis), meta-analysis with random-effects models.
5Q=Cochrane’s Q-statistic.
6I2=statistic for between study variance.
Bold numbers indicate genome-wide significant association in the meta-analysis.
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Figure 1. Expression analysis. Expression analysis of IL13 and CLEC16A
in various tissues (human scalp hair follicle cells, lymphocytes, and skin).
The first lane shows a size marker (O’GeneRuler 100 bp Plus DNA Ladder;
Fermentas, St Leon-Rot, Germany) and the last lane shows a negative control
(mock). IL13 was expressed in all three tissues analyzed. CLEC16A was
clearly expressed in scalp hair follicle cells and lymphocytes, whereas weak
expression was found in the skin.
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Twenty-three SNPs were selected on the basis of the results of
the US GWAS (Petukhova et al., 2008), and an association analysis
was performed in the present AA patient–control collective.
Of the eight susceptibility loci surpassing genome-wide significance
(Pp5 107), no SNPs from the following three genome-
wide significant loci—HLA, CTLA4, and IL-2RA—were included,
as strong association with these loci has been observed in previous
studies (Olsen et al., 2004; Entz et al., 2006; John et al., 2011; and
unpublished data). One resp. two SNPs were selected from the
remaining five of the eight loci. This resulted in a total of eight SNPs
from five genomic regions. A total of 163 SNPs were obtained with
nominal significance in the US GWAS (Po1 104). From these, we
first excluded those located in the eight previously reported genome-
wide significant loci. We then selected one SNP from each gene
known to be implicated in immune processes (Wills-Karp et al.,
1998; Hakonarson et al., 2007; ANZgene, 2009), resulting in 12
SNPs. In addition, we selected one SNP from each genomic region
with a P-value of on 106, which resulted in an additional four
SNPs. SNPs rs10104470, located in an intronic region of the CSMD1
gene, and rs2870951, located in the IL-26 gene, were rejected by the
software during assay design (for methods see below). The latter was
replaced by rs4913277. This SNP is in high linkage disequilibrium
with rs2870951 (r2¼ 0.89) and was the second best SNP of IL-26 in
the US GWAS.
Genotyping of the selected SNPs was carried out on the
MassArray system using a Sequenom Compact MALDI-TOF device
and iPLEX Gold reagents (Sequenom, San Diego, CA) in multiplex
reactions. Primer sequences and standard assay conditions are
available upon request. SNP call rates of 490% were required for
the analysis, and samples with call rates of o90% were excluded.
All the selected markers achieved call rates of 490% and were
thus included in the analysis. The samples of two individuals were
excluded owing to a genotyping call rate of o90%. No other
samples were excluded for failing quality control.
The FAMHAP software package (Herold and Becker, 2009) was
used for the association analyses. The Armitage trend test was used
for the single-marker analyses (Armitage, 1955). All of the 23 SNPs
included in the analyses were required to meet the following quality
criteria: minor allele frequency 41%; P-Hardy-Weinberg equi-
librium (PHWE) in cases 40.001; and PHWE in controls 40.05.
No SNP had to be excluded on the basis of these quality criteria. In
addition, no significant differences in genotype or allele frequencies
were observed between male and female participants in either the
patients or the controls (data not shown).
A meta-analysis of the German and US data was performed using
a random-effects model (Higgins et al., 2003) and a fixed-effects
model, as described previously (de Bakker et al., 2008). Allelic OR
were weighted using their standard errors to obtain a combined
OR estimate for both studies. First, the total variance Q was
computed, according to Cochrane (1954). From this, we computed
the between-study variance I2 according to Higgins et al. (2003).
I2 was then used to adjust the meta-analysis formula for the fixed-
effects model. Note that for some SNPs (e.g., rs694739) the between-
study variance is estimated to be zero. Therefore, the results for the
fixed- and the random-effects model coincide.
Correction for multiple testing was not performed, as the
five replicated loci had reached genome-wide significance in
the US GWAS (Petukhova et al., 2010) and the two loci identified
in this study reached genome-wide significance in the meta-
analysis.
Interaction was tested using the logistic regression framework
(Cordell and Clayton, 2002), as implemented in the interaction
software INTERSNP (Herold et al., 2009). The test for allelic
interaction was conducted with 1 degree of freedom. The test for
genotypic interaction was conducted with 4 degree of freedom. The
complete sample was then analyzed with ethnicity (European/US) as
an additional covariate.
Expression analysis of IL13 and CLEC16A was performed using
mRNA from human scalp hair follicle cells and immortalized
lymphocytes from healthy controls. RNA was extracted using the
RNeasy Plus Micro Kit (Qiagen) according to the manufacturer’s
instructions. In addition, we used human skin poly(A)þ RNA (BD
Biosciences, Heidelberg, Germany) and performed first-strand
complementary DNA synthesis of the RNAs with the M-MLV
Reverse Transcriptase (Promega, Mannheim, Germany). For subse-
quent PCR reactions, 1ml of each complementary DNA was used in
a 25-ml reaction. The obtained products were separated on a 1.5%
tris-borate-EDTA agarose gel and visualized under UV light.
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